Microneedle Array Technologies

Introduction to Microneedle Array Technologies

A microneedle array (MNA) sensor swaps the single wire of a conventional continuous glucose monitor for a patch of very short needles that stop in the upper layers of skin. The CGMs most people know from Dexcom, Abbott and Medtronic don't use microneedles [5]. Microneedles are up to about 1 millimeter long [5]. That is just long enough to cross the stratum corneum, the skin's outer barrier, and reach interstitial fluid, the fluid around cells whose glucose tracks blood glucose closely [5][6].

The appeal is comfort. A needle that short usually stays above the nerves and blood vessels deeper in the dermis, which is why reviewers describe microneedle sampling as painless [6]. Treat that as a design rationale from the research literature, not a tested promise: we didn't find a pain or comfort claim in the FDA's decision summary for Biolinq Shine, the microneedle glucose sensor covered below [4].

Key Architectures

How a microneedle reaches the fluid depends on how it's built. One review sorts them into solid, hollow, dissolvable and swellable needles, with coated needles built on solid ones [6]. Three of those matter most for glucose sensing:

• Solid Coated Needles: The sensing chemistry sits on the needle's surface, so the needle itself works as an electrode. In a typical glucose design, the enzyme glucose oxidase on the needle reacts with glucose, and the electrode reads a current that rises with the glucose level [5]. Biolinq Shine uses this principle, with seven microelectrodes in the papillary dermis, the top layer of the dermis [4].
• Hollow Needles: A channel runs through the needle. Some designs draw interstitial fluid up the channel by capillary action; one prototype placed a complete electrochemical cell inside a 700-micrometer hollow silicon needle [5]. The fluid can feed more than one sensor: one research biosensor used a 3D-printed hollow array to monitor ketones and glucose together [5]. Hollow needles are harder to make than solid ones, and without internal support they can bend sideways during insertion [6].
• Swelling Hydrogels: Needles made from a water-absorbing gel (a hydrogel) go in stiff and dry, then swell as they soak up interstitial fluid without dissolving [6]. Researchers have mostly used them to collect fluid for later analysis, and one review notes they're cheap to make with high production yields [5][6]. One group built a conductive hydrogel needle that measured glucose directly in rats for 3 hours [5]. Hydrogels that swell in response to glucose itself also exist, but the ones in the review we read were built to release insulin, not to measure glucose [5].

Leading Innovators

As of October 2026, microneedle glucose sensing is no longer only a research project. One company has an FDA-authorized product, and another product that often appears alongside it has no FDA authorization:

• Biolinq: The FDA granted Biolinq's De Novo request for the Biolinq Shine Autonomous Time-in-Range Microsensor on September 23, 2025, as a prescription device [2][4]. On September 18, 2026, it cleared 510(k) K262599, which adds over-the-counter use; Biolinq's summary says the sensing technology is unchanged [3]. Shine measures glucose only. The FDA lists its measurand as "glucose in interstitial fluid" [4]. Here's what surprised us when we read the decision summary: the wearable shows no numbers at all. A colored light on the device shows the glucose range, an optional app adds detail, and the sensor lasts up to five days [4]. It's labeled for adults 22 and older who don't take insulin and must not be used by people with type 1 diabetes [4]. Both FDA documents say users shouldn't take medical action based on its output without a qualified healthcare professional, so any treatment change is a decision for your care team [3][4]. Biolinq's own technology page describes a "multi-sensor platform for sensing multiple analytes" and marks it as an investigational device [1]. We found no FDA record of a Biolinq product that measures ketones or anything else besides glucose [2][3][4]. We also couldn't confirm from a primary source when the over-the-counter version goes on sale.
• PKVitality: PKvitality, a company based in France, developed the K'Watch, a watch-style monitor with a replaceable sensor that reads interstitial fluid glucose through microneedles and a glucose oxidase reaction [8]. A peer-reviewed survey, with searches current to December 2020, listed it as neither FDA-cleared nor CE-marked [8]. As of October 2026, searches of the FDA's 510(k) and premarket approval databases return no PKvitality records [9][10]. The K'Watch has no FDA authorization.

Technical Challenges

Getting a short needle to work reliably in living skin is harder than its size suggests. The reviews and FDA documents we read point to several hurdles:

• The 'bed of nails' effect: Skin is elastic and under tension, and pressing many needles in at once behaves differently from pushing in one. A modeling study of array insertion into human skin says the mechanics are complex "due in part to a 'bed of nails' effect" [7]. In that model, the base plate holding the needles cut penetration efficiency by up to 24%, and penetration varied by 27% across a row of five needles [7].
• Mechanical failure of needles. Silicon microneedles are mechanically strong, yet parts of them can break off under the skin [6]. Hollow needles can bend during insertion, as noted above [6].
• Signal problems from low ISF volumes and interference from sweat. Designs that pull fluid out of the skin can wait a long time for enough of it: in one early silicon array, it took 20 to 30 minutes to collect enough interstitial fluid to fill the needle's bore [6]. Sweat and leaking tissue fluid can also interfere with a wearable sensor's sensitivity [6]. Medications matter too. In testing reported to the FDA, acetaminophen, hydroxyurea and xylose pushed Shine's readings high [4].

Current R&D Focus

Most of the open work is about making these sensors last longer and cost less. One review calls for better protection against biofouling, the buildup of proteins and cells on the sensor tip, to stretch microneedle wear toward 15 days, in line with common CGM platforms [5]. Shine is labeled for five [4]. The same review says the enzyme and other sensing layers need protecting during insertion and storage, and that sterilization methods need careful assessment [5]. For Shine, Biolinq validated e-beam sterilization [4].

Material choice drives cost. Silicon needles need expensive fabrication equipment, which one review names as a key limit on their wide use [6]. Polymer-based fabrication, usually by casting in a reverse mold, produces needles that are biocompatible, strong enough to pierce skin and easy to manufacture [6]. Adhesion counts as well: Shine is held on by an adhesive patch and can't be reapplied once it falls off [4].

Conclusion

Microneedle arrays have moved from the lab to one FDA-authorized product, and that product's limits show how far the field still has to go. Shine's authorization covers adults not on insulin, five-day wear and color ranges instead of numbers [4]. We also looked for evidence that microneedle sensors have less lag than conventional CGMs and didn't find a head-to-head comparison. The delay between blood and interstitial glucose differs from person to person, and it shifts with activity and with whether glucose is rising or falling, so a single lag figure can't be relied on [8]. One dermal microneedle prototype showed about 10 minutes of lag in testing [5]. Moving past Shine's narrow label will take large clinical studies, which one review names as a requirement before microneedle sensor arrays reach practical medical use [5].